Aileron Therapeutics is a clinical stage company discovering and developing novel medicines for the treatment of cancer and for cancer supportive care by targeting high value and historically undruggable intracellular targets using a proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a first-in-class dual MDM2/MDMX inhibitor that has been tested in hematologic cancers and is currently being evaluated in a Phase 2 clinical trial in combination with Pfizerâs palbociclib (IbranceÂŽ) for the treatment of MDM2-amplified advanced solid cancers, and in an upcoming Phase 1b/2 clinical trial to evaluate ALRN-6924 as a myelopreservative agent to protect against chemotherapy-induced toxicities. Emerging ALRN-6924 clinical and substantial preclinical data support its use across multiple cancer types as a combination therapy with targeted agents, chemotherapies, and immuno-oncology drugs. Aileron Therapeutics is exploring collaboration opportunities regarding ALRN-6924 and for its research in areas such as targeted protein degradation, HIF1-Îą, and the Bcl-2 family of cancer targets. Source
No articles found.
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its diffe...
Mersana Therapeutics is a clinical-stage biopha...
Synthorx is a biotechnology company focused on prolonging and improving the lives ...
Synthorx is a biotechnology company focused on ...
JanOne, formerly Appliance Recycling Centers of America, Inc., and subsidiaries, i...
JanOne, formerly Appliance Recycling Centers of...
Sierra Oncology is a clinical stage drug development company advancing targeted th...
Sierra Oncology is a clinical stage drug develo...
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-i...
Aerpio Pharmaceuticals is a biopharmaceutical c...
Ascendis Pharma is applying its innovative technology platform to build a leading,...
Ascendis Pharma is applying its innovative tech...
Join the National Investor Network and get the latest information with your interests in mind.